LOC729837 inhibitors Wortmannin and LY294002 both target the PI3K/AKT signaling pathway, which is fundamental in regulating cell growth, survival, and metabolism. Triciribine also targets AKT, which is a key player in the same pathway. These inhibitors can alter the phosphorylation state of downstream proteins, potentially affecting LOC729837 if its activity is modulated by AKT-mediated phosphorylation. Bortezomib and MG132 are both proteasome inhibitors, which can lead to the accumulation of proteins within the cell by preventing their degradation. This can influence the turnover of LOC729837 if it is normally ubiquitinated and degraded by the proteasome. Cyclopamine and DAPT target the hedgehog and Notch signaling pathways, respectively, and can alter cell fate decisions, possibly affecting LOC729837 if it is part of these developmental pathways.
Imatinib, Sorafenib, and SB431542 inhibit tyrosine kinases, RAF, and the TGF-beta receptor, respectively. These inhibitors can prevent the activation of signaling cascades that are essential for cell proliferation, survival, and differentiation. If LOC729837 is a component of any of these pathways or is regulated by them, these inhibitors can modulate its activity. Lastly, PD0332991 (Palbociclib) is a CDK4/6 inhibitor that prevents cell cycle progression, potentially affecting LOC729837 if it is involved in the regulation of the cell cycle.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that can inhibit downstream AKT signaling, potentially affecting LOC729837 if it is regulated by the PI3K/AKT pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
An AKT inhibitor that can prevent AKT activation, possibly influencing LOC729837 activity if AKT signaling modulates it. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
A hedgehog signaling pathway inhibitor that can alter cell growth and differentiation, potentially affecting LOC729837 if it is part of this pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can affect protein degradation pathways, potentially influencing LOC729837 stability or turnover if it is regulated by ubiquitination. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
A gamma-secretase inhibitor that can affect Notch signaling, potentially altering LOC729837 if it is involved in Notch pathway. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A tyrosine kinase inhibitor that can affect various signaling pathways, possibly influencing LOC729837 if it has tyrosine kinase activity or is regulated by tyrosine phosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can affect cell growth and autophagy, potentially affecting LOC729837 if it is involved in these processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
An inhibitor of the TGF-beta receptor that can affect cell proliferation and differentiation, potentially influencing LOC729837 if it is part of the TGF-beta signaling pathway. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
A CDK4/6 inhibitor that can halt cell cycle progression, potentially affecting LOC729837 if it is involved in cell cycle regulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A RAF inhibitor that can affect the MAPK signaling pathway, potentially influencing LOC729837 if it is regulated by this pathway. | ||||||